| Document |
Document Title |
|
WO/2024/089180A1 |
The present invention relates to a method to determine the recovery rate of sample extracellular vesicles. The present invention further relates to a kit comprising a control extracellular vesicle. The present invention also relates to m...
|
|
WO/2024/091053A1 |
The present invention relates to a method for predicting the response to immunotherapeutic agents, comprising a step of measuring, in cancer cells or cancer tissue, the expression level of a dexamethasone-induced ras-related protein 1 (D...
|
|
WO/2024/089297A1 |
Disclosed are methods to obtain enhanced variants of fluorescent and bioluminescent proteins based on ratiometric measurement of luminescence. Disclosed are furthermore engineered variants of a yellow fluorescent protein (YFP) derived fr...
|
|
WO/2024/086891A1 |
The present invention relates generally to the identification and/or treatment of cancer and in particular cancers in which gastrin releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates ...
|
|
WO/2024/087602A1 |
An isothermal amplification detection device, comprising a temperature control platform (100), a reaction platform (200), a plurality of first heat conduction members (300), and a plurality of second heat conduction members (400). The te...
|
|
WO/2024/090863A1 |
The present specification provides a method for predicting the prognosis of endometrial cancer and a kit using same, the method comprising the steps of: detecting whether MSH2 or MSH6 is deficient in a biological sample isolated from an ...
|
|
WO/2024/090872A1 |
The present invention relates to a method and a kit for rapidly diagnosing tsutsugamushi on the basis of genetic scissors. More specifically, the present invention relates: to a molecular diagnosis method for rapidly detecting Orientia t...
|
|
WO/2024/091598A1 |
A nucleotide sequencing device includes a plurality microfluidic chips configured for nucleic acid sequencing and a reagent dispensing manifold with at least one dispensing port wherein the manifold is operable to move in at least two di...
|
|
WO/2024/091026A1 |
Provided is an electrode for detecting an extracellular matrix-degrading enzyme, the electrode specifically binding to an extracellular matrix-degrading enzyme and having excellent adsorption selectivity. One embodiment of the present in...
|
|
WO/2024/090455A1 |
A multiple sclerosis diagnostic method according to the present invention comprises: a step for measuring the relative abundance of a bacterium contained in a saliva sample collected from a subject; and a step for performing (1) or (2) b...
|
|
WO/2024/091909A1 |
Described are methods of inducing a protective immune response against Lassa virus comprising administering a prophylactically effective amount of a nucleic acid molecule encoding a Lassa virus glycoprotein precursor (LASV GPC) to a subj...
|
|
WO/2024/089673A1 |
Biomarkers that can be used for the detection and/or aid in the diagnosis of disease states, preferably pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), PH in chro...
|
|
WO/2024/089242A1 |
The invention also relates to the use of a kit or a process according to the invention for the detection of a target nucleic acid and for the diagnosis of a disease or a condition. A kit and a method according to the present invention ar...
|
|
WO/2024/090864A1 |
Provided in the present specification are a method for diagnosing endometrial cancer using a nectin-4 expression rate, and a kit using same, the method comprising the steps of: measuring a nectin-4 expression rate in a biological sample ...
|
|
WO/2024/091124A1 |
The present disclosure relates to systems and methods for analysis of proteins, more in particular to nanopore systems, devices and methods for single- molecule protein analysis and sequencing. Provided is a method for translocating a ta...
|
|
WO/2024/089437A1 |
There is provided methods for diagnosing or aiding diagnosis of pulmonary hypertension (PH), pulmonary arterial hypertension (PAH), and/or chronic thromboembolic pulmonary hypertension (CTEPH) in a subject, determining a subject's risk o...
|
|
WO/2024/086899A1 |
The present disclosure relates to a method of separation of charged substances by electrophoresis by using an inorganic thread. It includes contacting an electrolyte with an outer surface of the inorganic thread to cause wetting the oute...
|
|
WO/2024/091874A1 |
Disclosed herein are compositions comprising a MTRES1 gene therapy. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a MTRES1 gene therapy.
|
|
WO/2024/092158A1 |
Methods of preparing stabilized cell-free nucleic acid control material in a body fluid are provided. Compositions including stabilized cell-free nucleic acid control materials and methods of their use are also provided. Kits including t...
|
|
WO/2024/091573A1 |
Disclosed are systems and methods for rapidly generating general reaction conditions using a closed-loop workflow leveraging matrix down-selection, machine learning, and robotic experimentation. In certain aspects, provided is a method, ...
|
|
WO/2024/091990A1 |
Described are methods of treating human papillomavirus (HPV) type 16- or HPV type 18-related High-grade Squamous Intraepithelial Lesion (HSIL) of the cervix. The described methods comprise evaluating one or more biological samples for th...
|
|
WO/2024/092190A2 |
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respir...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
|
WO/2024/087405A1 |
A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.
|
|
WO/2024/089639A1 |
The disclosure provides, at least in part, formulation buffers suitable for lentiviral vectors.
|
|
WO/2024/090265A1 |
This information processing device 1 comprises: a storage unit 12 which stores a prognosis estimation model that has been trained to output the prognosis of a patient upon receiving input data including a spatial distribution of at least...
|
|
WO/2024/089028A1 |
According to a first aspect of the present invention, a digital amplification method is provided for detecting and quantifying DNA and for determining degradation and/or integrity of the DNA, in particular male DNA in a sample, wherein t...
|
|
WO/2024/092194A2 |
Provided herein are compositions, kits, and methods useful for photolabeling and enrichment of biomolecules of interest. The probes of the composition may include reactive probes. The reactive probes may be used for labeling molecules an...
|
|
WO/2024/091445A1 |
Provided herein are methods for treating cholestasis in a subject having liver disease. More specifically, the present invention relates to methods for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in a subject where the ...
|
|
WO/2024/089415A1 |
The invention relates to a method of diagnosing a cancer in a subject, wherein the method comprises determining the expression level of a set of miRNAs in a sample obtained from the subject. The invention also relates to a method of iden...
|
|
WO/2024/086878A1 |
The disclosure relates to a screening system configured to identify biological agents, biological differences, pathogens and/or genetic differences. The screening system may include an incubation zone having an incubation station for inc...
|
|
WO/2024/006460A9 |
Biomarkers and machine learning techniques to identify biomarkers are disclosed herein. In one particular implementation, the present disclosure relates to the identification of biomarkers to be used in the detection and diagnosis of LD....
|
|
WO/2024/087070A1 |
The present application relates to the technical field of biology, and specifically relates to a plasmid target, primer probe, kit and method for detecting residual host cell DNA in a cellular preparation or viral preparation. The plasmi...
|
|
WO/2024/091607A1 |
Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are methods of treating renal cancer based on expression levels of canc...
|
|
WO/2024/092165A1 |
Disclosed herein is a method for diagnosing a mycobacterial infection in a subject. The method comprises performing acetonitrile fractionation of a subject sample to deplete depleted in high molecular weight proteins. The sample is enzym...
|
|
WO/2024/092227A1 |
The disclosure relates to methods for treating a malignancy in a subject with a cell therapy, methods of predicting a likelihood of response to the cell therapy product in the subject, and methods of predicting a likelihood of CAR T-cell...
|
|
WO/2024/087080A1 |
An immersion objective, an optical system and a detection method. The immersion objective sequentially comprises, in the direction from an object side (S) to an image side, a first lens group (G1) having a positive focal power, at least ...
|
|
WO/2024/089533A2 |
A process challenge to be used for determining the effectiveness of a sterilization procedure is provided. The process challenge device includes a stack including a plurality of test sheets disposed on top of each other. The process chal...
|
|
WO/2024/091052A1 |
The present invention relates to: a method for discovering disease biomarkers through comparison of diseased- and normal-tissue-specific epigenomes and a normal body fluid epigenome; and the like. The present invention relates to a metho...
|
|
WO/2024/091509A1 |
A device where saliva from a pregnant woman in the first trimester of pregnancy (6-8 weeks of pregnancy) is mixed with a chaotropic agent that facilitates cell lysis and protein denaturization. The mixture is introduced into a microfluid...
|
|
WO/2024/089689A1 |
The presently disclosed subject matter provides methods for diagnosing breast cancer. It relates to the identification of unique T cell receptor (TCR) CDR3 clones whose frequency in the subject's TCR repertoire sequencing data is indicat...
|
|
WO/2024/090962A1 |
A learning propensity information determination system based on genetic test information, according to one embodiment, comprises: a basic information generation unit for generating basic information by receiving information about a teste...
|
|
WO/2024/089662A1 |
Biomarkers that can be used for the detection and/or aid in the diagnosis of disease states, preferably pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH), to methods of treating PH or PAH in a subject are described. Al...
|
|
WO/2024/089314A1 |
Massive sequencing panel composed of 37 genes for liquid biopsy that allows the early diagnosis of breast cancer and methods for obtaining useful data for the diagnosis and follow-up of the disease.
|
|
WO/2024/091545A1 |
Nucleic acid error suppression is provided. In various embodiments, DNA is extracted from a collection of plasma samples. A sequence library with duplex adapters is prepared. The library is prepared by ligating a duplex adapter having a ...
|
|
WO/2024/087105A1 |
An automated sheet operating device, a method of using same, and a spatial omics analysis system. The automated sheet operating device (100) comprises: a first driving apparatus (110) and an end effector (120) which is mounted so as to b...
|
|
WO/2024/089027A1 |
The present invention relates to a method for assessing the status of nucleic acid degradation and/or integrity of one or more nucleic acids in a sample, comprising the steps of digitally amplifying at least two regions within at least o...
|
|
WO/2024/090458A1 |
The purpose of the present invention is to provide: a substance which has an activity of binding to an inhibitory KIR to inhibit the cytotoxic activity of an NK cell and is useful for allogeneic technologies associated with organ transpl...
|
|
WO/2024/089417A1 |
The present invention relates to methods of predicting whether a subject having a cancer or a pre-cancer would benefit from treatment with an immune checkpoint inhibitor, as well as methods for treating subjects determined to be likely t...
|
|
WO/2024/091477A1 |
Provided herein is an automated euglobulin clot lysin assay method for calculating a euglobulin clot lysis time from a plasma sample in an amount of less than about 75 μL. Also disclosed here in a kit analyzing the euglobulin clot lysis...
|
